China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from the Phase I/II study for its bispecific antibody (BsAb) CM336, used for treating relapsed or refractory multiple myeloma (R/R M/M), at the 66th American Society of Hematology (ASH) Annual Meeting.
Phase I/II Study Design and Safety Assessment
The Phase I/II study aimed to assess the safety, tolerability, and preliminary efficacy of CM336 in patients with R/R MM. As of October 30, 2024, 68 subjects were enrolled, all of whom had been previously treated with proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, with a median of four-line treatment. The safety assessment indicated that CM336 demonstrated good safety and tolerability, with the dose successfully increased to 160 mg without reaching the maximum tolerated dose.
CM336’s Mechanism and Licensing Deal
CM336 is an in-house developed bispecific antibody targeting BCMA and CD3. Last month, Keymed Biosciences out-licensed the ex-Greater China rights of CM336 to UK firm Platina Medicines Ltd (PML) in a deal valued at USD 620 million. This strategic partnership highlights the potential of CM336 in the global market for treating multiple myeloma.-Fineline Info & Tech
